Across TCGA pan-cancer cohorts, H2AC4 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated H2AC4 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher H2AC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated H2AC4 expression acts as an unfavorable survival marker.
COAD and SKCM are the cancer types where H2AC4 Mutation most reproducibly stratifies survival.